StreetInsider.com News Articles

Form 4 PACIFIC BIOSCIENCES OF For: Aug 10 Filed by: Van Oene Mark

Tue, 11 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260811/26907322.html

Form 4 PACIFIC BIOSCIENCES OF For: Aug 10 Filed by: Van Oene Mark

Tue, 11 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260811/26907322.html

Form S-8 PACIFIC BIOSCIENCES OF

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886965.html

Form S-8 PACIFIC BIOSCIENCES OF

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886965.html

Form 10-Q PACIFIC BIOSCIENCES OF For: Jun 30

Thu, 06 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26885729.html

Form 10-Q PACIFIC BIOSCIENCES OF For: Jun 30

Thu, 06 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26885729.html

Pacific Bio (PACB) Misses Q2 EPS by 1c

Wed, 05 Aug 2026 16:26:18 -0400

Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $39 million versus the consensus estimate of $40.69 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

Form 8-K PACIFIC BIOSCIENCES OF For: Jul 30

Wed, 05 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26874852.html

Form 8-K PACIFIC BIOSCIENCES OF For: Jul 30

Wed, 05 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26874852.html

PacBio names Mark Van Oene as CEO, replacing Christian Henry

Wed, 05 Aug 2026 16:08:11 -0400

Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective Aug. 5, 2026.

Van Oene, who previously served as the company's Chief Operating Officer since joining PacBio in 2021, succeeds Christian Henry, who stepped down after six years in the role. Van Oene has also been appointed to PacBio's Board of Directors.

Henry will remain on the Board of Directors and has agreed to serve as a business advisor to the company through at least the end of 2026 to support the transition.

John Milligan, Ph.D., Chair of

PacBio names Mark Van Oene as CEO, replacing Christian Henry

Wed, 05 Aug 2026 16:08:11 -0400

Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective Aug. 5, 2026.

Henry will remain on the Board of Directors and has agreed to serve as a business advisor to the company through at least the end of 2026 to support the transition.

John Milligan, Ph.D., Chair of

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective August 5, 2026. Mr. Van Oene, who has served as Chief Operating Officer, succeeds Christian Henry, who has stepped down as President and Chief Executive Officer after six years leading PacBio. Mr. Van Oene has also been appointed to serve on PacBio's Board of Directors, effective August 5, 2026. Mr. Henry will continue

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Wed, 05 Aug 2026 16:08:00 -0400

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection

PacBio Announces Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.

Recent Business Highlights

Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer
Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at $345 USD list price per genome with enhanced methylation detection

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

Wed, 05 Aug 2026 09:05:00 -0400

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry and an accompanying software update for its Vega systems. Together, the updates expand the range of HiFi applications laboratories can run in-house and allow customers to match sequencing performance and run time to specific project needs.

Vega SPRQ-Nx brings the same core chemistry used on the high-throughput Revio system to Vega, increasing output from 60 Gb to 90 Gb of HiFi data per run. PacBio is also lowering the

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

Wed, 05 Aug 2026 09:05:00 -0400

Vega SPRQ-Nx brings the same core chemistry used on the high-throughput Revio system to Vega, increasing output from 60 Gb to 90 Gb of HiFi data per run. PacBio is also lowering the

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

Wed, 05 Aug 2026 09:05:00 -0400

Vega SPRQ-Nx brings the same core chemistry used on the high-throughput Revio system to Vega, increasing output from 60 Gb to 90 Gb of HiFi data per run. PacBio is also lowering the

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

Wed, 05 Aug 2026 09:05:00 -0400

Vega SPRQ-Nx brings the same core chemistry used on the high-throughput Revio system to Vega, increasing output from 60 Gb to 90 Gb of HiFi data per run. PacBio is also lowering the

PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Tue, 28 Jul 2026 16:05:00 -0400

MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts.

A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is

PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Tue, 28 Jul 2026 16:05:00 -0400

A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is